CA
NZ
UK
AU
IND
US
CVRx, Inc. (NASDAQ:CVRX), a medical-device company commercializing its Barostim neuromodulation therapy for heart failure, reported growing revenue in the second quarter of 2026 but continued losses, and execution challenges pressured its outlook. The stock has hit a rough patch as investors weigh the promise …
Boston Scientific Corporation (NYSE:BSX), one of the largest medical-device companies, delivered another quarter of strong sales and earnings in the second quarter of 2026, yet its stock hit a rough patch after the company cut its full-year guidance and investors focused on emerging competition …
Biote Corp. (NASDAQ:BTMD), a company focused on hormone-optimization therapy delivered through a network of trained practitioners, hit a setback in the second quarter of 2026 as a product recall weighed on sales and pushed it to a loss. The stock rose anyway, as investors …
SS Innovations International, Inc. (NASDAQ:SSII), a developer of surgical robotic systems aimed at making robotic surgery more affordable, saw its shares fall even as it posts rapid growth and expands its installed base across a dozen countries. With a differentiated, cost-focused platform gaining traction …
LifeVantage Corporation (NASDAQ:LFVN), a direct-selling health-and-wellness company, just slipped after reporting fiscal fourth-quarter results that missed expectations and declining to provide guidance amid a CEO transition. For investors, the setback focuses attention on what comes next for a company navigating soft demand, aLeadershipchange and …
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN), a clinical-stage biotechnology company developing treatments for neurodegenerative diseases, lit up the screen with a sharp one-day gain, the kind of move that is common in micro-cap biotech and that says as much about the stock'sVolatilityas about any single event. …
MindWalk Holdings Corp. (NASDAQ:HYFT) is a company in the midst of reinvention, and understanding it requires knowing its recent history: it is the former ImmunoPrecise Antibodies, rebranded in September 2025 as it repositioned from a wet-lab antibody-services provider into an AI-focusedBiologicsplatform company. After a …
EyePoint, Inc. (NASDAQ:EYPT), a biopharmaceutical company focused on treatments for serious eye diseases, saw its shares fall after delivering a pivotal Phase 3 readout that was decidedly mixed, missing its primary endpoint while showing standout durability data. For investors, the setup is unusually nuanced, …
Context Therapeutics Inc. (NASDAQ:CNTX), a clinical-stage biotechnology company developing bispecific antibodies for cancer, has seen its shares under pressure even as it reports encouraging early data and secures regulatory support for its lead program. For investors, the pullback poses the classic biotech question: a …
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company developing T-cell receptor (TCR) engineered therapies, has seen its shares under pressure even as it pushes its lead program into a pivotal trial and reports encouraging early data. For investors, the pullback poses the familiar biotech …
Please wait processing your request...